NEWPORT BEACH, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announced that Chief Executive Officer Dr. Jordan R. Plews, PhD will be presenting at the Los Angeles Bioscience Ecosystem Summit Twenty 24 (“LA-BEST”) conference on Thursday May 23, 2024. LA-BEST is the
NEWPORT BEACH, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the first quarter ended March 31, 2024. Elevai Labs CEO, Jordan R. Plews, PhD stated, "This quarter, Elevai Labs has demonstrated remarkable year-over-year revenue growth while
Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy (DMD)1. Elevai believes that EL-22 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1
Elevai Labs established two subsidiaries: Elevai Biosciences, Inc., and Elevai Skincare, Inc. Elevai Biosciences will focus on acquiring and developing biopharmaceutical technologies with initial focus on the development of EL-22 and EL-32, the lead assets targeting indications associated with obesity. Elevai Skincare will continue commercializing exosome skincare technologies for the medical dispensed skincare market. NEWPORT
Agreement adds two drug candidates to product pipeline consisting of (i) “EL-22”, a clinical stage engineered probiotic expressing myostatin, and (ii) “EL-32”, a preclinical engineered probiotic expressing dual myostatin & activin-A. Exclusive license covers global rights excluding South Korea. Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of
Five international distribution agreements signed to date Cumulative contracted minimum purchase requirements of $4.9M in the first five years Up to five additional international distribution agreements in discussion NEWPORT BEACH, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- ELEVAI Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a medical aesthetic company specializing in physician-dispensed skincare, announces significant strides in global distribution and highlights
-  Taiwan is ELEVAI’s third Asian contract for exosomes distribution after adding the Philippines in August of 2023 and Vietnam in May 2023-  Asia-Pacific represents a combined $13 Billion prestige skincare and luxury haircare market4,5 -  Immediate access to 40 specialty hair treatment clinics and four (4) high-end medical aesthetic clinics Newport Beach, CA –April,
Company reports record annual revenues of $1.71 Million for 2023, up 123.5% over the previous year Company reports record Q4 2023 revenues of $698,591, up 403% from Q4 2022  NEWPORT BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported financial results
ELEVAI Physician-Dispensed Skincare Now Available Direct to Consumers Newport Beach, CA – March, 18th 2023 – ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skin care, is proud to announce the launch of its online E-commerce portal. The new E-commerce portal serves as a business-to-business (B2B) extension of the Company’s existing
Utility Patent Covers the formulation for ELEVAI’s flagship exosome-based skin care products Newport Beach, CA – January 24, 2023 - ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, is pleased to announce today that the United States Patent & Trademark Office (USPTO) issued US Patent No. 11,878,038, entitled “Exosome-based Skincare Product”
Newport Beach, CA – January, 17 2023 - ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced certain preliminary, unaudited management-prepared financial results for the fiscal year ended December 31, 2023. These results are based on the most current information available to management, are unaudited, and subject to the completion of the
ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-costNewport Beach, CA – January 16, 2024 - Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement
Newport Beach, CA – January, 2 2023 - ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, announces participation in three aesthetic industry conferences in the first quarter of 2024. 1. Octane Aesthetic Technology Forum (ATF) in Newport Beach, California (January 24-25, 2024): ELEVAI's Third Consecutive Year as a Corporate Sponsor ELEVAI
Company Records Record Quarterly Revenues For Immediate Release Newport Beach, CA – December 11, 2023 – Elevai Labs Inc. (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported financial results for its Q3 2023 fiscal quarter, ended September 30, 2023. “We are proud to announce a record setting quarter for Elevai marked by exceptional
Newport Beach, CA - December 7th, 2023 - Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce its new partnership with Skin Sana Ltd. a Serbian corporation and premier luxury skincare distributor based in Belgrade covering territories that include Serbia, Albania, North Macedonia, Kosovo and Bosnia-Herzegovina. This
Newport Beach, CA - November 29th, 2023 - Elevai Labs, Inc. (Nasdaq: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced that they have signed a licensing agreement with Yuva Biosciences, Inc. to research and develop means to incorporate Yuva Bioscience’s mitochondrial research with ELEVAI’s PREx™ (Precision Regenerative Exosome Technology™) to potentially develop topical
Newport Beach, CA – November 24, 2023 - ELEVAI LABS, INC. (Nasdaq: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today announced the closing of its previously announced initial public offering of 1,500,000 shares of common stock at a public offering price of $4.00 per share for total gross proceeds of $6,000,000, before deducting
Newport Beach, CA - November 20, 2023 – Elevai Labs, Inc., a medical aesthetic company specializing in physician-dispensed skincare, today announced the pricing of its initial public offering. The Offering consists of 1,500,000 shares of common stock at a public offering price of $4.00 per share, for total gross proceeds of $6,000,000 before deducting underwriting
Newport Beach, CA – August 1, 2023 – ELEVAI Labs, Inc, a medical aesthetic biotechnology company focused on physician-dispensed skincare and leader in exosome research and development, is pleased to announce its new partnership with Dmark Multisales Corporation, a prominent marketing and distribution company based in the Philippines. This strategic collaboration will see Dmark Multisales Corp.
Patented Exosome Skincare Line Now Available in the MENA Region Newport Beach, CA – June 8, 2023 - ELEVAI Labs Inc., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, is pleased to announce its new international distributor agreement with Central Circle Company W.L.L in Kuwait. This strategic partnership marks ELEVAI Labs' expansion into the
Newport Beach, CA - May 18, 2023 - ELEVAI Labs Inc., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, proudly announces COSBEAUTY Ltd., a subsidiary of Viet Can Trading and Service Co., Ltd, as the exclusive distributor of ELEVAI Skincare products in Vietnam, expanding the international footprint of its exosome-based cosmetic skincare products. The ELEVAI E-Series™ product range, a pre-and
NEWPORT BEACH, CA – April 26, 2023 – ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, is pleased to report a stem cell exosome research partnership with Dr. Stanislav Sokolenko’s Lab at Dalhousie University and a non-repayable Grant from the Mitacs Accelerate Grants Program (“Mitacs”). Mitacs is an organization that funds
NEWPORT BEACH, CA – April 5, 2023 – ELEVAI LABS, INC., a science-based, data-driven aesthetic skincare company, will launch its revolutionary core technology platform, PREx™ (Precision Regenerative Exosome Technology™) from The American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Phoenix on April 13th. Co-Founded by Dr. Jordan Plews, a Stanford-trained scientist with
ELEVAI and EVOLVE To Celebrate New Partnership During AMWC Conference North America Newport Beach, CA - February 21, 2023 - ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, proudly announces EVOLVE Medical Inc. as the exclusive distributor of ELEVAI Skincare products in Canada. The ELEVAI E-Series™ product range, a pre-and post-procedure skincare system developed with a proprietary stem
Former Evolus and Allergan Executive to Support the Company's Mission of Leading the Regenerative Skincare Market Newport Beach, CA - February 7, 2023 - ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in physician-dispensed skincare, proudly announces the addition of Crystal Muilenburg as an independent member of the company’s Board of Directors.  Crystal brings
ELEVAI LABS RETURNS TO INDUSTRY-LEADING OCTANE AESTHETICS TECH FORUM “People’s Choice Award” Winner Presents Groundbreaking Exosome Technology Newport Beach, CA - January 17, 2023 - ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in regenerative skincare, returns to the prestigious Octane Aesthetics Tech Forum on January 27 at the Balboa Bay Resort in Newport Beach,
NEWPORT BEACH, Calif., Nov. 29, 2022 /PRNewswire/ -- ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in regenerative skincare, proudly announces that cosmetic industry veteran James R. Headley joins the team as a Strategic Advisor. James R. Headley Mr. Headley, previously CEO of ZO Skin Health, will play an active role in supporting the ELEVAI management team as it
Co-Founder & CEO Jordan R. Plews, Ph.D. Presents Key Considerations For an Emerging New Class of Regenerative Skincare NEWPORT BEACH, Calif., Nov. 1, 2022 /PRNewswire/ -- ELEVAI LABS, INC., a medical aesthetic biotechnology company specializing in regenerative skincare, announces its sponsorship and participation in the upcoming Global Aesthetics Conference taking place November 3-5 in Miami. The Future of Skincare is Now A new era
Chris Kraneiss DAVIS, Calif., Aug. 17, 2022 /PRNewswire/ -- ELEVAI LABS, INC., ("ELEVAI" or the "Company") a science-based, data-driven regenerative aesthetic skincare company is pleased to announce the appointment of industry veteran Chris Kraneiss as Chief Commercial Officer. Mr. Kraneiss holds a proven track record of building successful medical aesthetic businesses within top globally recognized brands. Mr. Kraneiss
"THE KOL MEETING FOR KOL'S" DAVIS, Calif., June 6, 2022 /PRNewswire/ -- ELEVAI LABS, INC., ("ELEVAI" or the "Company") a science-based, data-driven regenerative aesthetic skincare company is pleased to announce that Co-Founder and CEO Dr. Jordan Plews has been selected to speak at the world-renowned Beauty Through Sciences Symposium as a Stem Cell Exosome Key
DAVIS, Calif., May 23, 2022 /PRNewswire/ — ELEVAI LABS, INC., (“ELEVAI” or the “Company”) a science-based, data-driven regenerative aesthetic skincare company is pleased to announce it has retained Univest Securities, LLC for investment banking and advisory services.About Univest Securities, LLC Registered with FINRA since 1994, Univest Securities, LLC provides a wide variety of financial services
DAVIS, Calif., April 29, 2022 /PRNewswire/ — ELEVAI LABS, INC., (“ELEVAI” or the “Company”) a science-based, data-driven regenerative aesthetic skincare company is pleased to announce the appointment of industry expert Brenda Buechleras Chief Marketing and Brand Advisor. Ms. Buechler has an extensive and successful career that spans over 23 years in director and leadership roles
DAVIS, Calif., Aug. 17, 2022 /PRNewswire/ — ELEVAI LABS, INC., (“ELEVAI” or the “Company”) a science-based, data-driven regenerative aesthetic skincare company is pleased to announce the appointment of industry veteran Chris Kraneiss as Chief Commercial Officer. Mr. Kraneiss holds a proven track record of building successful medical aesthetic businesses within top globally recognized brands. Mr.
DAVIS, Calif., Jan. 25, 2022 /PRNewswire/ — ELEVAI LABS, INC., (“ELEVAI” or the “Company”) a biotech company leveraging the power of human stem cell exosomes to create next-generation topical skincare products, is pleased to announce that the company has won the LaunchPad SBDC People’s Choice Award at the 2022 Octane Aesthetics Tech Summit (“ATS”) held
DAVIS, Calif., Jan. 21, 2022 /PRNewswire/ — ELEVAI LABS, INC., (“ELEVAI” or the “Company”) a biotech company leveraging the power of human stem cell exosomes to create next-generation topical skincare products, is pleased to announce that it has signed a non-exclusive global distributor and trademark license agreement with leading Australian headquartered aesthetic device company DermapenWorld™
Aesthetics Tech Summit in Newport Beach, California. Jan 06 2022DAVIS, CALIFORNIA, Jan 06, 2022, ELEVAI LABS, INC., (“ELEVAI” or the “Company“) a biotech company leveraging the power of human stem cell exosomes to create next-generation topical skincare products, is pleased to announce that company co-founder and CEO, Jordan Plews, Ph.D., has been invited to present

E-Series Product Line Launching

DAVIS, CALIFORNIA, Dec 21, 2021 – ELEVAI Labs, Inc. (“ELEVAI”) is pleased to announce the much anticipated launch of its E-SERIES™ line of products. The E-SERIES is our post-treatment skincare line developed specifically for use following in-office aesthetic procedures. ELEVAI’s E-SERIES product line includes skincare formulations to support and enhance the results of in-office aesthetic